The burgeoning interest in incorporating psychedelics into therapeutic practices has seen a marked rise over the past few years. Recent...
During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Tom McDonald of Clerkenwell Health. Clerkenwell Health...
Clairvoyant Therapeutics is pleased to announce that the first clinical trial participant in Finland enrolled in CLA-PSY-201 has received their first...
The article Lucy Scientific Acquires Psychedelic Assets from Wesana Health was originally published on Microdose. Last month, a new psychedelic firm joined...
Many starry-eyed entrepreneurs view the psychedelic industry as radically new; unfortunately, it may end up collapsing in on itself like cryptocurrency. The...
Microsoft today announced that its new AI-enabled Bing will now allow users to generate images with Bing Chat. This new feature is powered by DALL-E, OpenAI’s...
The CEO of Synthesis speaks out about the recent bankruptcy of the Dutch sister company that left the U.S. practitioner training program in upheaval. The...
The article Canadians Launch Petition to Legalize Psilocybin Therapy: Could it Work? was originally published on Microdose. As scientific evidence accumulates,...
Although many people say they would have to be given a general anaesthetic to fall asleep on shrooms, others find that during a trip, what they...
The article News You Might Have Missed: March 20th, 2023 was originally published on Microdose. Welcome to the News You Might Have Missed, a weekly roundup...
Analysts have long expected a contraction, but when it hit it still felt sudden and strange. The post The Psychedelics Finance Crunch Seen in the SXSW...
The article Irwin Naturals Backs Out of Deal To Buy Braxia Scientific was originally published on Microdose. Back in January, we reported that Irwin Naturals...
“Nobody does creature work the way Wētā does,” Craig Mazin, co-creator of HBO’s “The Last of Us,” said in the official podcast for the video...
This year’s SXSW brought together psychedelic professionals and media celebrities for a festive and starry-eyed look at an arguably precarious industry. The...
R&A PSYINS, an independent insurance broker that provides necessary insurance coverages to the psychedelic medicinal industry, today announced a strategic...
The article Filament Health Announces FDA Approval Of Phase II Clinical Trial was originally published on Microdose. Filament Health has announced FDA...